According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
YMAB has been the topic of a number of other research reports. Cowen reiterated a “buy” rating on shares of Ovid Therapeutics in a report on Monday, July 1st. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Protalix Biotherapeutics in a research note on Monday, June 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $30.80.
Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.07). Analysts forecast that Y-mAbs Therapeutics will post -1.95 EPS for the current year.
In related news, insider Thomas Gad sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $22.40, for a total transaction of $89,600.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 28,000 shares of company stock worth $592,880 in the last 90 days. 38.40% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in Y-mAbs Therapeutics by 2,178.9% during the fourth quarter. BlackRock Inc. now owns 341,831 shares of the company’s stock valued at $6,952,000 after purchasing an additional 326,831 shares in the last quarter. Citigroup Inc. acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $37,000. Northern Trust Corp acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $1,533,000. Geode Capital Management LLC acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $1,587,000. Finally, American International Group Inc. acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $93,000. Hedge funds and other institutional investors own 24.80% of the company’s stock.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Recommended Story: Cost of equity and a company’s balance sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.